Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Wang

Showing results (261-270 of 276) with videos related to

Pageof 28
Sort By:
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
European Urology|March 15, 2026
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate CancerBrian F Chapin, Marc Smaldone, Amado J Zurita, et al.
Nature Communications|July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications|April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
JCI Insight|November 25, 2025
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Nature Communications|April 5, 2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancersOmar Alhalabi, Jianfeng Chen, Yuxue Zhang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 8, 2025
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled TrialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
Pageof 28

Showing results (261-270 of 276) with videos related to

Sort By:
Pageof 28
Iscience|February 6, 2024
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer baseHongying Duan, Angela R Corrigan, Cheng Cheng, et al.
European Urology|March 15, 2026
A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate CancerBrian F Chapin, Marc Smaldone, Amado J Zurita, et al.
Nature Communications|July 4, 2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Nature Communications|April 13, 2022
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapySang T Kim, Yanshuo Chu, Mercy Misoi, et al.
Cancer Cell|May 8, 2026
Dendritic cell redundancy enables priming of anti-tumor CD4<sup>+</sup> T cells in pancreatic cancerCourtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, et al.
JCI Insight|November 25, 2025
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Nature Communications|April 5, 2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancersOmar Alhalabi, Jianfeng Chen, Yuxue Zhang, et al.
Medrxiv : the Preprint Server for Health Sciences|April 8, 2025
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled TrialMeggan Mackay, Catriona A Wagner, Ashley Pinckney, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
Pageof 28